Evercore says this biotech stock is a high risk, high reward play

Evercore ISI initiated coverage of an immunology and inflammation drug developer at an outperform, saying the market is underpricing its odds for success.

Related Keywords

Gavin Clark Gartner ,Bristol Myers Squibb ,Aclaris Therapeutics ,Bristol Myers Squibb Co ,Aclaris Therapeutics Inc ,Breaking News Investing ,Investment Strategy ,Health Care Industry ,Biotechnology ,Pharmaceuticals ,Business News ,